
Patients enrolled and randomized in core study, n=198
Pasireotide 40 mg, n=65
Pasireotide 60 mg, n=65
Active control, n=68
Discontinued, n=6
• AE, n=2
• Withdrew consent, n=2
• Administrative problems, n=2
Discontinued, n=8
• AE, n=4
• Withdrew consent, n=2
• Administrative problems, n=2
• Protocol deviation, n=1
Discontinued, n=3
• Withdrew consent, n=2
• Protocol deviation, n=1
Patients completed core study, n=181
Pasireotide 40 mg, n=59
Pasireotide 60 mg, n=57
Active control, n=65
Patients entered extension study, n=174
Pasireotide 40 mg, n=57
Pasireotide 60 mg, n=54
Crossover, n=62
Discontinued, n=29
• Unsatisfactory therapeutic effect, n=15
• Withdrew consent, n=6
• AE, n=4
• Death, n=2
• Protocol deviation, n=2
Discontinued, n=29
• Unsatisfactory therapeutic effect, n=9
• Withdrew consent, n=8
• AE, n=8
• Administrative problems, n=2
• Lost to follow-up, n=1
• Protocol deviation, n=1
Discontinued, n=28
• Unsatisfactory therapeutic effect, n=13
• Withdrew consent, n=8
• AE, n=8
Patients completed extension study, n=87
Pasireotide 40 mg, n=28
Pasireotide 60 mg, n=25
Crossover, n=34